Complex brain arteriovenous malformations (bAVMs) in ≥3 Spetzler-Martin grades have long been challenges among cerebrovascular diseases. None of the traditional methods, such as microsurgical operation, endovascular intervention, or stereotactic radiotherapy, can completely eliminate complex bAVMs without a risk of neural function deterioration. The multistaged hybrid operation solved part of the challenge but remained risky in the installment procedures and intervals. The one-staged hybrid operation was applied in the surgical treatment of cerebrovascular diseases and proved to be a potentially safe and effective method for curing complex bAVMs. However, lacking the support of high-level evidence, its advantages remain unclear. This study was proposed to validate the benefits and risks of one-staged hybrid operation in the treatment of complex bAVMs, as well as its indications, key technologies, and workflows.
The study is being conducted from Jan 2016 to Dec 2020 with 20 cooperation units. It consists of 2 sets. The registry set is designed as a prospective real-world registry. The trial set is designed as a prospective pragmatic clinical trial, specifically for the patients with perforating arterial feeders. The two sets share a common grouping: the traditional operation group and the one-staged hybrid operation group. The assignment is based on the clinical condition in the registry set and is randomized in the trial set. End points will be evaluated at scheduled time points. The safety and efficiency of one-staged hybrid operation in treating complex bAVMs will be validated.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
1,200
An integrated procedure that consists of microsurgery, intraoperative DSA, endovascular intervention techniques and other assistance tools. All the procedures are performed in a one-staged operation without any intermission or any transfer of patients.
The classical mode of operations in neurosurgery. The operation is performed with neurosurgical instruments and microscope. Some of assisting tools can be used in the operation, such as neuro-navigation, Doppler probe, neural electrophysiological monitoring and so on. But neither the intraoperative DSA nor endovascular intervention techniques is used in the operation
Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, China
RECRUITINGBeijing Tiantan Hospital Capital Medical University
Beijing, Beijing Municipality, China
RECRUITINGGeneral Hospital of Rocket Army
Beijing, Beijing Municipality, China
RECRUITINGQilu Hospital, Shandong University
Jinan, Shandong, China
RECRUITINGQingdao Municipal Hospital
Qingdao, Shandong, China
RECRUITINGHuashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
RECRUITINGThe Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
RECRUITINGneural function deterioration
Increasing of mRS and mRS\>2
Time frame: 3 months after operation
neural function deterioration in 6 months
Increasing of mRS and mRS\>2
Time frame: 6 months after operation
neural function deterioration in 12 months
Increasing of mRS and mRS\>2
Time frame: 12 months after operation
postoperative mortality
the fatality due to operation
Time frame: 7 days after operation
operation-related complications
any complications that occur within 7 days from the date of operation, including intracranial hemorrhage or infarction, infection of the central nervous system, infection of the respiratory system, cranial nerve deficits, and other symptomatic complications
Time frame: 7 days after operation
postoperative bAVMs residue
the bAVMs residue revealed by postoperative DSA or computed tomographic angiography
Time frame: 7 days after operation
3 months bAVMs residue
the bAVMs residue revealed by postoperative DSA or computed tomographic angiography
Time frame: 3 months after operation
6 months bAVMs residue
the bAVMs residue revealed by postoperative DSA or computed tomographic angiography
Time frame: 6 months after operation
12 months bAVMs residue
the bAVMs residue revealed by postoperative DSA or computed tomographic angiography
Time frame: 12 months after operation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.